BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 32184103)

  • 1. VEGF receptor 2 inhibitor nintedanib completely reverts VEGF-A
    Deissler HL; Stutzer JN; Lang GK; Grisanti S; Lang GE; Ranjbar M
    Exp Eye Res; 2020 May; 194():108004. PubMed ID: 32184103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking of VEGF-A is not sufficient to completely revert its long-term effects on the barrier formed by retinal endothelial cells.
    Deissler HL; Rehak M; Busch C; Wolf A
    Exp Eye Res; 2022 Mar; 216():108945. PubMed ID: 35038456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VEGF but not PlGF disturbs the barrier of retinal endothelial cells.
    Deissler HL; Deissler H; Lang GK; Lang GE
    Exp Eye Res; 2013 Oct; 115():162-71. PubMed ID: 23891860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Single Routes of Intracellular Signaling is Not Sufficient to Neutralize the Biphasic Disturbance of a Retinal Endothelial Cell Barrier Induced by VEGF-A165.
    Deissler HL; Lang GK; Lang GE
    Cell Physiol Biochem; 2017; 42(4):1493-1513. PubMed ID: 28719888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transport and fate of aflibercept in VEGF-A
    Deissler HL; Sommer K; Lang GK; Lang GE
    Exp Eye Res; 2020 Sep; 198():108156. PubMed ID: 32712182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells.
    Deissler HL; Lang GK; Lang GE
    Exp Eye Res; 2014 May; 122():20-31. PubMed ID: 24631334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impairment of the Retinal Endothelial Cell Barrier Induced by Long-Term Treatment with VEGF-A
    Deissler HL; Rehak M; Wolf A
    Biomolecules; 2022 May; 12(5):. PubMed ID: 35625661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sitagliptin and the Blood-Retina Barrier: Effects on Retinal Endothelial Cells Manifested Only after Prolonged Exposure.
    Jäckle A; Ziemssen F; Kuhn EM; Kampmeier J; Lang GK; Lang GE; Deissler H; Deissler HL
    J Diabetes Res; 2020; 2020():2450781. PubMed ID: 32566677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of VEGF-A is sufficient to abrogate the disturbing effects of VEGF-B together with VEGF-A on retinal endothelial cells.
    Deissler HL; Lang GK; Lang GE
    Graefes Arch Clin Exp Ophthalmol; 2015 Jun; 253(6):885-94. PubMed ID: 25663437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VEGF modulation of retinal pigment epithelium resistance.
    Ablonczy Z; Crosson CE
    Exp Eye Res; 2007 Dec; 85(6):762-71. PubMed ID: 17915218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of vascular endothelial growth factor (VEGF) is sufficient to completely restore barrier malfunction induced by growth factors in microvascular retinal endothelial cells.
    Deissler HL; Deissler H; Lang GE
    Br J Ophthalmol; 2011 Aug; 95(8):1151-6. PubMed ID: 21273213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor-A
    Ved N; Hulse RP; Bestall SM; Donaldson LF; Bainbridge JW; Bates DO
    Clin Sci (Lond); 2017 Jun; 131(12):1225-1243. PubMed ID: 28341661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of protein kinase C is not sufficient to prevent or reverse effects of VEGF165 on claudin-1 and permeability in microvascular retinal endothelial cells.
    Deissler HL; Deissler H; Lang GE
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):535-42. PubMed ID: 19643968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Internalization of bevacizumab by retinal endothelial cells and its intracellular fate: Evidence for an involvement of the neonatal Fc receptor.
    Deissler HL; Lang GK; Lang GE
    Exp Eye Res; 2016 Feb; 143():49-59. PubMed ID: 26481553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dll4 Suppresses Transcytosis for Arterial Blood-Retinal Barrier Homeostasis.
    Yang JM; Park CS; Kim SH; Noh TW; Kim JH; Park S; Lee J; Park JR; Yoo D; Jung HH; Takase H; Shima DT; Schwaninger M; Lee S; Kim IK; Lee J; Ji YS; Jon S; Oh WY; Kim P; Uemura A; Ju YS; Kim I
    Circ Res; 2020 Mar; 126(6):767-783. PubMed ID: 32078435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decursin inhibits VEGF-mediated inner blood-retinal barrier breakdown by suppression of VEGFR-2 activation.
    Kim JH; Kim JH; Lee YM; Ahn EM; Kim KW; Yu YS
    J Cereb Blood Flow Metab; 2009 Sep; 29(9):1559-67. PubMed ID: 19536074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Claudin-3 and claudin-19 partially restore native phenotype to ARPE-19 cells via effects on tight junctions and gene expression.
    Peng S; Wang SB; Singh D; Zhao PY; Davis K; Chen B; Adelman RA; Rizzolo LJ
    Exp Eye Res; 2016 Oct; 151():179-89. PubMed ID: 27593915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis) in microvascular retinal endothelial cells.
    Deissler H; Deissler H; Lang S; Lang GE
    Br J Ophthalmol; 2008 Jun; 92(6):839-43. PubMed ID: 18511543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteopontin-induced vascular hyperpermeability through tight junction disruption in diabetic retina.
    Someya H; Ito M; Nishio Y; Sato T; Harimoto K; Takeuchi M
    Exp Eye Res; 2022 Jul; 220():109094. PubMed ID: 35490836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decorin inhibits angiogenic potential of choroid-retinal endothelial cells by downregulating hypoxia-induced Met, Rac1, HIF-1α and VEGF expression in cocultured retinal pigment epithelial cells.
    Du S; Wang S; Wu Q; Hu J; Li T
    Exp Eye Res; 2013 Nov; 116():151-60. PubMed ID: 24016866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.